Carl L. Gordon - 14 Feb 2025 Form 4 Insider Report for MBX Biosciences, Inc. (MBX)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: MBX
Reported as of: 14 Feb 2025
Net transaction value: +$2,020,756
SEC form: 4
Accepted by SEC: 19 Feb 2025, 17:56:33 UTC
Prior SEC filing: 13 Feb 2025
Next SEC filing: 11 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Carl L. Gordon

Key filing fact

Carl L. Gordon filed Form 4 for MBX Biosciences, Inc. (MBX) on 19 Feb 2025.

Key facts

This page summarizes Carl L. Gordon's Form 4 filing for MBX Biosciences, Inc. (MBX).
4 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 19 Feb 2025, 17:56.

Change

Previous filing in this sequence was filed on 13 Feb 2025.
Current net transaction value: +$2,020,756.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MBX transaction

Common Stock

Purchase

Transaction value: $177,824
Shares: +17,962
Change %: +0.57%
Price: $9.90
Shares after: 3,176,390
Date: 14 Feb 2025
Ownership: See footnotes
Footnotes: F1, F4, F6

MBX transaction

Common Stock

Purchase

Transaction value: $290,969
Shares: +29,540
Change %: +0.93%
Price: $9.85
Shares after: 3,205,930
Date: 14 Feb 2025
Ownership: See footnotes
Footnotes: F2, F4, F6

MBX transaction

Common Stock

Purchase

Transaction value: $531,919
Shares: +49,070
Change %: +1.5%
Price: $10.84
Shares after: 3,255,000
Date: 18 Feb 2025
Ownership: See footnotes
Footnotes: F3, F4, F6

MBX transaction

Common Stock

Purchase

Transaction value: $1,020,044
Shares: +94,100
Change %: +14%
Price: $10.84
Shares after: 747,887
Date: 18 Feb 2025
Ownership: See footnotes
Footnotes: F3, F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $9.58 to a high of $10.20 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.

Footnote F2

Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $9.80 to a high of $10.00 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.

Footnote F3

Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $10.25 to a high of $11.46 per share. The Reporting Person undertakes, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price.

Footnote F4

These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.

Footnote F5

These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by Genesis Master Fund and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.

Footnote F6

Each of OrbiMed Advisors, GP VII, Genesis GP, and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.